{"DataElement":{"publicId":"6774572","version":"1","preferredName":"Positron Emission Tomography London Deauville Criteria Point Scale Outcome Specify","preferredDefinition":"The free text field to specify the response to treatment of Hodgkins and Aggressive Non-Hodgkins Lymphoma using the London Deauville Criteria Scale.","longName":"5913664v1.0:2556910v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"5913664","version":"1","preferredName":"Positron Emission Tomography London Deauville Criteria Point Scale Outcome","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered._A 5 point scale devised to assess the response to treatment of Hodgkins and Aggressive Non-Hodgkins Lymphoma._The result of an action.","longName":"2230940v1.0:5913662v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2230940","version":"1","preferredName":"Positron Emission Tomography","preferredDefinition":"A noninvasive imaging method that provides information about cellular activity (metabolic information).  It is used along with magnetic resonance imaging (MRI) which provides information about the shape and size of the tumor (spatial information).","longName":"C17007","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7C5DB4E-AC57-18B5-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-05-24","modifiedBy":"ONEDATA","dateModified":"2005-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5913662","version":"1","preferredName":"London Deauville Criteria Point Scale Outcome","preferredDefinition":"A 5 point scale devised to assess the response to treatment of Hodgkins and Aggressive Non-Hodgkins Lymphoma.:The result of an action.","longName":"C99723:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"London Deauville Criteria Point Scale","conceptCode":"C99723","definition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"549B0E3B-5E6C-1396-E053-F662850A5724","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-07-18","modifiedBy":"ONEDATA","dateModified":"2017-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Deauville Criteria:London Deauville Criteria Point Scale","workflowStatus":"RELEASED","registrationStatus":"Application","id":"549B0E3B-5E7D-1396-E053-F662850A5724","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-07-18","modifiedBy":"COOPERM","dateModified":"2017-07-21","changeDescription":"Created for request by Y. Yakovlev on 7/14/17. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2556910","version":"1","preferredName":"Specify","preferredDefinition":"Be specific about something; define clearly.","longName":"SPEC","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2390957","version":"1","preferredName":"Specify","preferredDefinition":"Specify; be specific about something; define clearly.","longName":"C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FEED0CD5-44DE-6158-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-08-22","modifiedBy":"ONEDATA","dateModified":"2005-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"24FA6376-5316-2DE9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-29","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-12-19","modifiedBy":"REEVESD","dateModified":"2014-02-25","changeDescription":"10/20/08mn-added origin.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"specify","type":"Preferred Question Text","description":"specify","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A82B94C-263C-1843-E053-F662850AF799","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"MORENOC","dateModified":"2020-01-08","changeDescription":"1/8/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}